Bacterial Infectious Diseases Therapeutics Market to Reach US$228.48 Billion by 2035, Driven by Rising Antimicrobial Resistance

The global bacterial infectious diseases therapeutics market was valued at approximately USD 103.89 billion in 2025 and is forecasted to reach USD 228.48 billion by 2035, growing at a CAGR of 8.2% during the forecast period 2026-2035. The market is gaining momentum as the continued burden of bacterial infections, increasing demand for effective antimicrobial treatments, rising awareness of infectious diseases, and the need to address treatment-resistant bacterial infections support therapeutic development. Growing emphasis on improving infection management and expanding access to effective treatment options is further contributing to market growth.

The competitive opportunity is increasingly focused on innovative antibacterial therapies, improved treatment outcomes, and solutions targeting drug-resistant infections. Rising concerns surrounding antimicrobial resistance are encouraging pharmaceutical companies and researchers to explore new therapeutic approaches and strengthen the development pipeline. The market is therefore shifting toward next-generation antibacterial treatments, targeted therapies, improved infection management, and strategies addressing antimicrobial resistance, supporting continued expansion of the global bacterial infectious diseases therapeutics market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/bacterial-infectious-diseases-therapeutics-market?sai-v

Recent Developments
June 2026: GSK and Spero Therapeutics received U.S. FDA approval for Utebzi (tebipenem pivoxil hydrobromide) for adults with complicated urinary tract infections, including pyelonephritis, who have limited or no alternative oral treatment options. Utebzi is the first and only oral carbapenem antibiotic approved in the U.S. for this patient population, expanding treatment options for difficult bacterial infections.

May 2026: Armata Pharmaceuticals continued advancing its AP-SA02 bacteriophage therapy program for difficult-to-treat bacterial infections. The company reported progress across clinical, regulatory, and manufacturing activities supporting planned Phase 3 development, highlighting growing interest in pathogen-specific bacteriophage therapies as alternatives or complements to conventional antibiotics.

April 2026: Centauri Therapeutics received FDA Qualified Infectious Disease Product (QIDP) designation for CTX-187, an investigational antimicrobial immunotherapy targeting clinically prevalent and multidrug-resistant Gram-negative bacterial infections. The candidate is designed to combine immune-mediated antibacterial activity with direct antibacterial effects and is expected to progress toward first-in-human studies.

March 2026: The bacterial infectious diseases therapeutics pipeline continued shifting toward novel mechanisms and targeted approaches as antimicrobial resistance increases pressure on conventional antibiotic therapies. Research and development activity is increasingly focused on multidrug-resistant Gram-negative pathogens, bacteriophages, antimicrobial immunotherapies, and other alternatives designed to address infections with limited treatment options.

February 2026: The FDA finalized guidance on defining durations of use for certain medically important antimicrobial drugs in food-producing animals, reinforcing antimicrobial stewardship efforts aimed at reducing unnecessary antimicrobial exposure and supporting efforts to limit the development and spread of antimicrobial resistance. These regulatory initiatives remain relevant to the broader bacterial infectious diseases therapeutics landscape.

Key Players
Novartis AG | GlaxoSmithKline plc | Pfizer Inc. | Merck & Co., Inc. | Sanofi | Allergan | Bayer AG | AstraZeneca plc | Bristol-Myers Squibb Company | Takeda Pharmaceutical Company Limited | Eli Lilly and Company | Johnson & Johnson | Teva Pharmaceuticals Industries Ltd. | Others

Key Highlights
Novartis AG - Holds a 7.2% share, supported by its broad pharmaceutical portfolio, strong R&D capabilities, and global presence across innovative therapies.

GlaxoSmithKline plc - Holds a 5.5% share, driven by its extensive pharmaceutical portfolio, global commercial presence, and strong research capabilities.

Pfizer Inc. - Holds an 8.5% share, supported by its large-scale pharmaceutical portfolio, global reach, and strong innovation capabilities.

Merck & Co., Inc. - Holds a 6.5% share, strengthened by its innovative medicines portfolio and extensive global R&D capabilities.

Sanofi - Holds a 5.9% share, driven by its diversified pharmaceutical portfolio, specialty medicines, and international commercialization capabilities.

Allergan - Maintains a competitive position through its specialty pharmaceutical portfolio and established presence across multiple therapeutic areas.

Bayer AG - Holds a 3.6% share, supported by its diversified healthcare portfolio and global pharmaceutical operations.

AstraZeneca plc - Holds a 5.2% share, driven by its strong prescription medicine portfolio, R&D capabilities, and focus on innovative therapies.

Bristol-Myers Squibb Company - Holds a 4.5% share, supported by its innovative pharmaceutical portfolio and strong focus on specialty and advanced therapies.

Takeda Pharmaceutical Company Limited - Holds a 3.3% share, strengthened by its diversified specialty pharmaceutical portfolio and global presence.

Eli Lilly and Company - Holds a 3.9% share, driven by its innovative medicines portfolio, strong research capabilities, and global commercial reach.

Johnson & Johnson - Holds a 6.9% share, supported by its broad healthcare portfolio, global presence, and strong pharmaceutical capabilities.

Teva Pharmaceuticals Industries Ltd. - Maintains a competitive position through its broad pharmaceutical portfolio, specialty medicines, and extensive global distribution network.

Others - Include additional pharmaceutical companies, specialty drug manufacturers, and emerging players contributing to the competitive landscape.

Get the Full Report Here: https://www.datamintelligence.com/buy-now-page?report=bacterial-infectious-diseases-therapeutics-market?sai-v

Market Drivers
- Rising global burden of bacterial infectious diseases, increasing demand for effective antibacterial therapeutics.

- Growing prevalence of antibiotic-resistant bacterial infections, driving demand for novel antibiotics and alternative treatment approaches.

- Increasing healthcare expenditure and expanding access to infectious disease diagnosis and treatment across developed and emerging markets.

- Rising adoption of advanced antimicrobial therapies for the management of complicated and drug-resistant bacterial infections.

- Increasing investment in research and development of next-generation antibiotics, antibacterial agents, and targeted therapies.

- Growing awareness of antimicrobial resistance (AMR) and increasing government initiatives focused on infection control and responsible antibiotic use.

- Rising demand for rapid and accurate bacterial infection diagnosis to support timely and targeted therapeutic intervention.

Industry Developments
- Increasing development of novel antibiotics and antibacterial therapies targeting multidrug-resistant bacterial pathogens.

- Growing clinical research into bacteriophage therapy, antimicrobial peptides, monoclonal antibodies, and other alternative approaches to conventional antibiotics.

- Strategic collaborations between pharmaceutical companies, biotechnology firms, academic institutions, and government organizations to accelerate antimicrobial drug development.

- Increasing investment in antimicrobial resistance research and development programs to address the growing threat of drug-resistant infections.

- Development of rapid diagnostic technologies designed to identify bacterial pathogens and antimicrobial susceptibility more efficiently.

- Expansion of antibiotic stewardship programs and initiatives focused on optimizing antimicrobial use while reducing the development of resistance.

Regional Insights
North America - 41% share: "Driven by advanced healthcare infrastructure, high infectious disease treatment expenditure, strong pharmaceutical R&D capabilities, and increasing focus on antimicrobial resistance."

Europe - 30% share: "Supported by established healthcare systems, government-led antimicrobial resistance initiatives, advanced diagnostic capabilities, and increasing development of novel antibacterial therapies."

Asia Pacific - 23% share: "Fueled by the high burden of bacterial infections, large patient populations, improving healthcare infrastructure, rising healthcare expenditure, and increasing awareness of antimicrobial resistance."

Latin America - 4% share: "Supported by improving access to infectious disease diagnosis and treatment, expanding healthcare infrastructure, and increasing efforts to address antibiotic resistance."

Middle East & Africa - 2% share: "Driven by rising infectious disease burden, improving healthcare access, increasing availability of antibacterial therapies, and growing investment in healthcare infrastructure."

Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/bacterial-infectious-diseases-therapeutics-market?sai-v

Key Segments
➥ By Disease Type

Bacterial Skin Infections: Represents a significant segment, driven by the high prevalence of bacterial skin conditions, increasing diagnosis and treatment of infections, and continued demand for effective antibacterial therapies.

Foodborne Bacterial Infections: Represents a major segment, supported by the persistent incidence of bacterial foodborne diseases, growing awareness of food safety, and increasing need for timely antimicrobial treatment.

Sexually Transmitted Bacterial Infections: Represents a significant and growing segment, fueled by the continued prevalence of bacterial sexually transmitted infections, improved screening and diagnosis, and increasing access to antimicrobial treatment.

Others: Represents a growing segment, supported by the broad range of bacterial infections requiring therapeutic intervention and ongoing demand for effective antibacterial treatments.

➥ By Therapeutics

Beta-Lactam: Represents the dominant segment, driven by their extensive use against a broad range of bacterial infections, established clinical efficacy, and continued availability across multiple therapeutic applications.

Quinolones: Represents a significant segment, supported by their broad-spectrum antibacterial activity and continued use in the treatment of selected bacterial infections.

Macrolides: Represents an important segment, fueled by their use against respiratory, sexually transmitted, and other bacterial infections, particularly where alternative antibiotic options are required.

Tetracyclines: Represents a significant segment, driven by their broad antibacterial activity and continued application in the management of skin, sexually transmitted, and other bacterial infections.

Sulfonamide: Represents a moderate segment, supported by their continued use in selected bacterial infections and availability as established antibacterial treatment options.

Others: Represents a growing segment, fueled by continued development of novel antibiotics, combination therapies, and alternative antibacterial treatment approaches in response to evolving treatment needs.

➥ By Route of Administration

Oral: Represents the dominant segment, driven by convenience, ease of administration, widespread outpatient use, and the availability of numerous antibacterial therapies in oral formulations.

Topical: Represents a significant segment, supported by the localized treatment of bacterial skin infections and the availability of creams, ointments, and other topical antibacterial formulations.

Parenteral: Represents an important segment, fueled by the need for rapid and controlled drug delivery in severe, complicated, or hospital-acquired bacterial infections.

Others: Represents a growing segment, supported by the development and use of alternative drug delivery approaches for specific bacterial infections and patient requirements.

➥ By Distribution Channel

Hospital Pharmacies: Represents the dominant segment, driven by the treatment of severe and complicated bacterial infections, increasing hospitalization for serious infections, and the need for physician-supervised antimicrobial therapy.

Retail Pharmacies: Represents a significant segment, supported by the widespread availability of oral and topical antibacterial medications and the increasing management of uncomplicated infections in outpatient settings.

Online Pharmacies: Represents a rapidly growing segment, fueled by expanding digital pharmacy platforms, home-delivery services, improved access to prescription medications, and increasing preference for convenient medicine procurement.

Others: Represents a growing segment, supported by specialty distribution networks, institutional procurement, and alternative channels serving diverse healthcare settings.

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.